Notícias e Atividades da Pharming

Veja o organograma con seus 38 executivos principais

Biografias mais buscadas da Pharming

• Fabrice Chouraqui, Executive Director and Chief Executive Officer
• Jabine Van Der Meijs, Director
• Richard Peters, Chairman of the Board

Recentes movimentos de executivos em Pharming

• Leverne Marsh, ingressou na Companhia como President, Chief Commercial Officer  (Notícia publicada em 5 de fevereiro de 2026).

Criar um alerta
para seguir os movimentos de executivos da Pharming.

Pharming possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Pharming

• Pharming Group announces results of 2026 Annual General Meeting of Shareholders
• Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders
• Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026
• Pharming Group to report first quarter 2026 financial results and provide business update on May 7
• Pharming Group announces the 2026 Annual General Meeting of Shareholders
• Pharming Group to participate in April investor conferences
• Pharming Group announces the filing of its 2025 Annual Report and Form 20-F
• Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older
• Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older
• Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
• View more press releases Close

Redes sociais sobre Pharming

• Pharming na Wikipedia, Google News e Yahoo Finance
• Pharming na LinkedIn, X (Twitter) e YouTube